The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
Tag: New England Journal of Medicine
-
Alzheimer’s Drug May Benefit Some Patients, New Data Shows
The drug, lecanemab, made by Eisai and Biogen, also carried risks of brain swelling and bleeding and should be studied further, a report of the findings said.
-
Masks Cut Covid Spread in Schools, Study Finds
In a so-called natural experiment, two school districts in Boston maintained masking after mandates had been lifted in others, enabling a unique comparison.
-
The Disease Took Zara, Then Sara. Could Ayla Be Saved?
Two sisters in one family died from a genetic disorder. Before a third child with the disease was born, doctors hatched a plan to spare her of its effects.
-
Vitamin D Supplements Don’t Help Another Condition, Study Finds
The vitamin pills do not prevent bone fractures in most people or protect against many other diseases, adding to questions about medical guidance many now take for granted.